Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.77 |
| ▸ | TSHR | P16473 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | XBP1 | P17861 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.64 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075030 | 0.99 | MEN1 (0.81) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL5075053 | 0.95 | MEN1 (0.75) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL5075051 | 0.91 | DPP4 (0.70) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL5075295 | 0.87 | DPP4 (0.71) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL5075972 | 0.83 | MEN1 (0.83) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL5075081 | 0.82 | DPP4 (0.81) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL27582639 | 0.81 | DPP4 (0.67) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL5718933 | 0.81 | ALDH1A1 (0.81) | MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10309073 | 0.80 | ALDH1A1 (0.76) | MEN1KMT2ANPSR1TSHRALDH1A1 | |
| SCHEMBL555918 | 0.80 | ALDH1A1 (0.81) | MEN1KMT2ANPSR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | claimed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | claimed |
| EP-1561752-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-08-10 | — | — | EP | claimed |
| EP-1496877-A2 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK A/S (DK) | 2005-01-19 | — | — | EP | claimed |
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS BENDTZ (DK) | 2004-02-19 | — | — | US | claimed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | claimed |
| EP-1301187-A2 | HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2003-04-16 | — | — | EP | claimed |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | claimed |
| WO-2002002560-A2 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-01-10 | — | — | WO | claimed |
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | disclosed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| EP-1561752-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-08-10 | — | — | EP | disclosed |
| EP-1496877-A2 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| EP-1301187-A2 | HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | disclosed |
| WO-2002002560-A2 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | MEN1 4621/4885KMT2A 1635/4885NPSR1 3771/4885 |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | MEN1 4621/4885KMT2A 1635/4885NPSR1 3771/4885 |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | MEN1 1029/4885KMT2A 3177/4885NPSR1 249/4885 |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | MEN1 1029/4885KMT2A 3177/4885NPSR1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.